Eli Lilly Shares Outstanding 2010-2024 | LLY
Eli Lilly shares outstanding history from 2010 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Eli Lilly shares outstanding for the quarter ending September 30, 2024 were 0.905B, a 0.58% increase year-over-year.
- Eli Lilly 2023 shares outstanding were 0.903B, a 0.15% decline from 2022.
- Eli Lilly 2022 shares outstanding were 0.905B, a 0.77% decline from 2021.
- Eli Lilly 2021 shares outstanding were 0.912B, a 0.09% decline from 2020.
Eli Lilly Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
903 |
| 2022 |
905 |
| 2021 |
912 |
| 2020 |
913 |
| 2019 |
936 |
| 2018 |
1,034 |
| 2017 |
1,052 |
| 2016 |
1,062 |
| 2015 |
1,066 |
| 2014 |
1,074 |
| 2013 |
1,085 |
| 2012 |
1,117 |
| 2011 |
1,114 |
| 2010 |
1,106 |
| 2009 |
1,098 |
Eli Lilly Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
905 |
| 2024-06-30 |
904 |
| 2024-03-31 |
904 |
| 2023-12-31 |
903 |
| 2023-09-30 |
900 |
| 2023-06-30 |
903 |
| 2023-03-31 |
903 |
| 2022-12-31 |
905 |
| 2022-09-30 |
904 |
| 2022-06-30 |
903 |
| 2022-03-31 |
906 |
| 2021-12-31 |
912 |
| 2021-09-30 |
911 |
| 2021-06-30 |
910 |
| 2021-03-31 |
912 |
| 2020-12-31 |
913 |
| 2020-09-30 |
911 |
| 2020-06-30 |
911 |
| 2020-03-31 |
912 |
| 2019-12-31 |
936 |
| 2019-09-30 |
919 |
| 2019-06-30 |
925 |
| 2019-03-31 |
984 |
| 2018-12-31 |
1,034 |
| 2018-09-30 |
1,026 |
| 2018-06-30 |
1,030 |
| 2018-03-31 |
1,050 |
| 2017-12-31 |
1,052 |
| 2017-09-30 |
1,056 |
| 2017-06-30 |
1,057 |
| 2017-03-31 |
1,056 |
| 2016-12-31 |
1,062 |
| 2016-09-30 |
1,061 |
| 2016-06-30 |
1,060 |
| 2016-03-31 |
1,063 |
| 2015-12-31 |
1,066 |
| 2015-09-30 |
1,065 |
| 2015-06-30 |
1,066 |
| 2015-03-31 |
1,067 |
| 2014-12-31 |
1,074 |
| 2014-09-30 |
1,074 |
| 2014-06-30 |
1,076 |
| 2014-03-31 |
1,076 |
| 2013-12-31 |
1,085 |
| 2013-09-30 |
1,084 |
| 2013-06-30 |
1,084 |
| 2013-03-31 |
1,092 |
| 2012-12-31 |
1,117 |
| 2012-09-30 |
1,120 |
| 2012-06-30 |
1,119 |
| 2012-03-31 |
1,110 |
| 2011-12-31 |
1,114 |
| 2011-09-30 |
1,114 |
| 2011-06-30 |
1,114 |
| 2011-03-31 |
1,112 |
| 2010-12-31 |
1,106 |
| 2010-09-30 |
1,105 |
| 2010-06-30 |
1,104 |
| 2010-03-31 |
1,103 |
| 2009-12-31 |
1,098 |
| 2009-09-30 |
1,098 |
| 2009-06-30 |
1,097 |
| 2009-03-31 |
1,097 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$765.281B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
